[Articles] Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study

Related Posts

• Comparing Relapsed or Refractory CLL with Zanubrutinib and Ibrutnib Phase 3 Trial

  KEY TAKEAWAYS In the phase 3 head-to-head trial ((ALPINE)), zanubrutinib demonstrated superior progression-free survival compared…

• KTE-X19’s Study in Relapsed/Refractory MCL: 3-Year Follow-up Results

  KEY TAKEAWAYS A Phase 3 ZUMA-2 trial investigated the efficacy of KTE-X19, an autologous anti-CD19…

• Golidocitinib Shows Promise for Treating Refractory/Relapsed Peripheral T-Cell Lymphoma: JACKPOT8 Study Analysis

  KEY TAKEAWAYS Golidocitinib is an oral JAK1 inhibitor being assessed in a multinational, pivotal study…